Annovis Bio, Inc.
Close on Oct 19, 2026
- Market cap
- $36.02M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 14, 2026 | After market close | – | $-0.40 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 15, 2026 | After market close | – | $-0.63 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 16, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | After market close | – | $-0.37 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | After market close | – | $-0.32 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | After market close | – | $-0.32 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 21, 2025 | After market close | – | $-0.43 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | – | $-0.97 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 15, 2024 | Before market open | – | $-0.44 | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 3, 2024 | After market close | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 1, 2023 | During market hours | – | – | – |
Press releases
Announcements Annovis Bio filed with the SEC
and Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease
Other events · EX-99.1 to Form 8-K
Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Provides Corporate Updates and Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Annovis Announces $10 Million Underwritten Offering of Common Stock
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results
Results of operations · EX-99 to Form 8-K
Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of
Regulation FD disclosure · EX-99.1 to Form 8-K
Neuronal damage Inflammation Neurotoxic proteins Biomarker data in mild AD patients (MMSE 21 - 24) 10 Reductions in neurotoxic proteins, inflammation, and neuronal damage
Regulation FD disclosure · EX-99 to Form 8-K
Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results
Results of operations · EX-99 to Form 8-K
Annovis Announces $6 Million Registered Direct
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Annovis Provides Corporate Updates and Reports
Results of operations · EX-99.1 to Form 8-K
of Plan to Regain Listing Compliance
Regulation FD disclosure · EX-99.1 to Form 8-K
and Reports First Quarter 2025 Financial Results
Results of operations · Executive or director change · EX-99.1 to Form 8-K
LISTING STANDARD NOTICE FROM THE NYSE
Listing notice · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Annovis Provides Corporate Updates and Reports Fourth Quarter and
Results of operations · EX-99.1 to Form 8-K
Annovis Announces First Patients Entered into Pivotal Phase 3 Study
Regulation FD disclosure · EX-99.1 to Form 8-K
Annovis Bio, Inc. Announces Proposed Public
Material agreement · Other events · EX-99.1 to Form 8-K
Annovis Bio, Inc. Announces Pricing of $21 Million
Material agreement · Other events · EX-99.2 to Form 8-K
Closing of $21 Million Public Offering
Material agreement · Other events · EX-99.3 to Form 8-K
December 11, 2024 Development path to NDA for • Alzheimer’s disease • Parkinson’s disease Investor Update
Regulation FD disclosure · EX-99.1 to Form 8-K
Annovis Bio Reports Third Quarter Financial Results and Provides
Results of operations · EX-99.1 to Form 8-K
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs
Other events · EX-99.1 to Form 8-K
Annovis Files Three New Patents for Combination
Regulation FD disclosure · EX-99.1 to Form 8-K
Annovis Bio Reports Second Quarter Financial Results and Provides
Results of operations · EX-99.1 to Form 8-K
Annovis’ Lead Compound Enhances Cognition Synergistically
Regulation FD disclosure · EX-99.1 to Form 8-K
Annovis Bio Receives FDA Approval to Transition to New Crystal
Regulation FD disclosure · EX-99.1 to Form 8-K
Annovis Bio Announces New Data from
Regulation FD disclosure · EX-99.1 to Form 8-K
Annovis Bio’s Buntanetap Found Safe and
Regulation FD disclosure · EX-99.1 to Form 8-K
Investor Webcast 6/11/2024 NYSE: ANVS - People Focused, Purpose Driven, Passion Powered -
Regulation FD disclosure · EX-99.2 to Form 8-K
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor
Regulation FD disclosure · EX-99.1 to Form 8-K
New Publication in a Peer-Reviewed Journal
Regulation FD disclosure · EX-99.1 to Form 8-K
Annovis Bio Provides Corporate Updates and Announces
Results of operations · EX-99.1 to Form 8-K
UNBLINDING OF THE BUNTANETAP PHASE III DATA IN PARKINSON’S DISEASE
Regulation FD disclosure · EX-99.1 to Form 8-K
Annovis Bio CEO Maria Maccecchini Issues Letter
Regulation FD disclosure · EX-99.1 to Form 8-K
BIO PROVIDES CORPORATE UPDATES AND REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
BIO PROVIDES DATA ANNOUNCEMENT UPDATE FOR THE PHASE II/III STUDY OF BUNTANETAP IN ALZHEIMER’S DISEASE
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio Announces Launch of Proposed Public Offering
Material agreement · Results of operations · Other events · EX-99.1 to Form 8-K
Bio Announces Pricing of $7.5 Million Public Offering
Material agreement · Results of operations · Other events · EX-99.2 to Form 8-K
BIO RECEIVES POSITIVE RECOMMENDATION TO CONTINUE PHASE 2/3 TRIAL OF BUNTANETAP FOR alzheimer’S DISEASE PATIENTS FROM THE INDEPENDENT
Other events · EX-99.1 to Form 8-K